In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study evaluated the effectiveness and safety of opicapone (Ongentys) for the treatment of non-motor symptoms in patients with Parkinson's disease (PD). The data showed that opicapone improved the non-motor symptoms and quality of life (QoL) with manageable side effects in patients with PD. Some background Parkinson's disease...
Read More
In a nutshell This study evaluated depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormonal therapy such as androgen deprivation therapy (ADT). The data showed that almost half of the patients with prostate cancer receiving ADT diagnosed with depression do not receive a documented mental health...
Read More
In a nutshell This study investigated the effectiveness and safety of sugemalimab (Cejemly) after treatment with concurrent or sequential chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The data showed that sugemalimab significantly increased the survival without cancer worsening with manageable...
Read More
In a nutshell This study investigated the effect of total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (CRT) and planned adjuvant chemotherapy on the survival of patients with locally advanced rectal cancer (LARC). The data showed that TNT did not increase survival compared with standard CRT and planned adjuvant...
Read More
In a nutshell This study aimed to investigate the safety and risk of disease recurrence in breast cancer survivors who were treated with systemic (whole-body) hormone replacement therapy (HRT). This study concluded that use of HRT increased the risk of disease recurrence in these patients. Some background Some breast...
Read More
